摘要
目的探讨化疗联合自体细胞因子诱导的杀伤细胞（cytokine-induced killer,CIK）治疗晚期非小细胞肺癌（nonsmall cell lung cancer,NSCLC）的临床疗效及安全性。方法Ⅲa～Ⅳ期NSCLC患者72例,行单纯化疗（多西他赛＋顺铂）36例为对照组,行化疗联合自体CIK细胞免疫治疗36例为观察组,治疗2个周期评定疗效,随访观察2组无进展生存期、总生存期和安全性。结果观察组疾病控制率（77.8%）高于对照组（52.8%）（P〈0.05）,中位无进展生存期及总生存期（9个月,19个月）较对照组（6个月,10个月）明显延长（P〈0.05）;2组疾病总缓解率（33.3%vs 25.0%）比较差异无统计学意义（P〉0.05）;观察组1、2a生存率分别为58.3%、30.6%,对照组分别为33.3%、8.6%,2组比较差异有统计学意义（P〈0.05）;观察组治疗后Ⅲ～Ⅳ度骨髓抑制、恶心发生率（8.3%,33.3%）低于对照组（30.6%,61.1%）（P〈0.05）。结论化疗联合自体CIK细胞免疫治疗NSCLC安全性好,可延缓疾病进展,延长患者生存时间。
Objective To evaluate the therapeutic effect and safety of chemotherapy plus the application of autologous cytokine-induced killer（CIK）cells in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods Seventytwo patients with stage Ⅲa to Ⅳ NSCLC were divided into control group receiving docetaxel and cisplatin,and observation group receiving autologous CIK cells immunotherapy besides docetaxel and cisplatin,with 36 patients in each group.The therapeutic effective rates were evaluated after 2-cycle treatment and compared between two groups.Results The disease control rate was higher in observation group（77.8%）than that in control group（52.8%）（P〈0.05）.The medium progression-free survival and overall survival were longer in observation group（9,19 months）than those in control group（6,10months）（P〈0.05）.There was no significant difference in the overall response rate between two groups（33.3% vs 25.0%）（P〉0.05）.The 1-and 2-year survival rates were 58.3% and 30.6%in observation group,significantly higher than those in control group（33.3%,8.6%）（P〈0.05）,and the incidence of Ⅲ to Ⅳ degree myelosuppression and nausea were significantly lower in observation group（8.3%,33.3%）than those in control group（30.6%,61.1%）（P〈0.05）.Conclusion Chemotherapy plus the application of autologous CIK cells immunotherapy is safe,and can delay the disease progression and prolong the survival.
出处
《中华实用诊断与治疗杂志》
2015年第1期31-33,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然科学基金(81302120)
